Data 'missingness' leads to US FDA panel loss for Janssen's Xarelto in ACS
This article was originally published in Scrip
Executive Summary
Janssen Pharmaceuticals failed to convince a US FDA advisory panel on 23 May to recommend the company's oral anticoagulant Xarelto (rivaroxaban) in combination with aspirin plus a thienopyridine as a therapy to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).